Last reviewed · How we verify
Atazanavir + ritonavir + tenofovir + nucleoside
Atazanavir + ritonavir + tenofovir + nucleoside is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced patients. Also known as: BMS-232632, Reyataz.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Atazanavir + ritonavir + tenofovir + nucleoside |
|---|---|
| Also known as | BMS-232632, Reyataz |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Atazanavir is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir levels. Tenofovir and the nucleoside reverse transcriptase inhibitor block reverse transcriptase, preventing viral RNA conversion to DNA and integration into host cells.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Hyperbilirubinemia
- Nausea
- Diarrhea
- Headache
- Rash
- Renal dysfunction (tenofovir-related)
- Nephrolithiasis
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC (PHASE3)
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir + ritonavir + tenofovir + nucleoside CI brief — competitive landscape report
- Atazanavir + ritonavir + tenofovir + nucleoside updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Atazanavir + ritonavir + tenofovir + nucleoside
What is Atazanavir + ritonavir + tenofovir + nucleoside?
How does Atazanavir + ritonavir + tenofovir + nucleoside work?
What is Atazanavir + ritonavir + tenofovir + nucleoside used for?
Who makes Atazanavir + ritonavir + tenofovir + nucleoside?
Is Atazanavir + ritonavir + tenofovir + nucleoside also known as anything else?
What drug class is Atazanavir + ritonavir + tenofovir + nucleoside in?
What development phase is Atazanavir + ritonavir + tenofovir + nucleoside in?
What are the side effects of Atazanavir + ritonavir + tenofovir + nucleoside?
What does Atazanavir + ritonavir + tenofovir + nucleoside target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Also known as: BMS-232632, Reyataz
- Compare: Atazanavir + ritonavir + tenofovir + nucleoside vs similar drugs
- Pricing: Atazanavir + ritonavir + tenofovir + nucleoside cost, discount & access